<DOC>
	<DOCNO>NCT01196052</DOCNO>
	<brief_summary>This single-arm open-label study assess safety , feasibility , efficacy trastuzumab emtansine ( T-DM1 ) completion anthracycline-based adjuvant/neoadjuvant chemotherapy patient early HER2-positive breast cancer . Patients receive T-DM1 3.6 mg/kg intravenously Day 1 3-week cycle , 17 cycle .</brief_summary>
	<brief_title>A Study Trastuzumab Emtansine ( T-DM1 ) Sequentially With Anthracycline-based Chemotherapy , Adjuvant Neoadjuvant Therapy Patients With Early Stage Herceptin ( HER ) 2-positive Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Ado-trastuzumab emtansine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Maytansine</mesh_term>
	<criteria>Adult patient ≥ 18 year age . Locally advance , inflammatory , early stage , unilateral , histologically confirm invasive breast cancer document local laboratory ( patient inflammatory breast cancer must able core needle biopsy ) . Herceptin ( HER ) 2positive tumor , confirmed central test use immunohistochemistry ( IHC ) situ hybridization ( ISH ) method . Willingness receive anthracyclinebased chemotherapy receive doxorubicin/cyclophosphamide ( AC ) OR 5fluorouracil ( FU ) /epirubicin/ cyclophosphamide ( FEC ) similar dose schedule describe protocol part neoadjuvant adjuvant treatment . For woman childbearing potential men partner childbearing potential , agreement use highly effective , nonhormonal form contraception 2 effective form nonhormonal contraception patient and/or partner . Contraception use must continue duration study treatment least 6 month last dose study treatment . Male patient use condoms duration study . Specific country requirement follow . Negative result serum pregnancy test premenopausal woman reproductive capacity woman &lt; 12 month menopause . Patients may enroll AC/FEC chemotherapy complete . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Adequate hematologic , biochemistry , cardiac assessment . Stage IV breast cancer bilateral breast cancer . Pregnant breastfeed woman . History malignancy within previous 5 year , except contralateral breast cancer ductal carcinoma situ ( DCIS ) /lobular carcinoma situ ( LCIS ) , appropriately treat carcinoma situ cervix , nonmelanoma skin carcinoma , Stage I uterine cancer , cancer outcome similar mention . Radiation therapy , immunotherapy , biotherapy within 5 year study enrollment ; noncardiotoxic chemotherapy malignancy treat &gt; 5 year study enrollment allow . Patients receive AC/FEC similar fashion study treatment prescribe adjuvant neoadjuvant treatment breast cancer allow enroll study completion AC/FEC . No prior history cardiotoxic chemotherapy allow . Active cardiac history . Current chronic daily treatment oral corticosteroid equivalent . Patients severe dyspnea rest require supplementary oxygen therapy . Active , unresolved infection screen . Human immunodeficiency virus ( HIV ) , hepatitis B virus ( HBV ) , hepatitis C virus ( HCV ) infection . Major surgery within 4 week enrollment unrelated breast cancer . Patients concomitant radiotherapy + TDM1 may contraindicate yet radiation therapy plan . Known hypersensitivity study drug derivative , include murine protein . Grade ≥ 2 peripheral neuropathy Baseline .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>